COMMUNIQUÉS West-GlobeNewswire

SIGA Secures Contract Valued at Up to $15 Million from Canadian Department of National Defence to Purchase TPOXX®
28/10/2026
Continues Canada's commitment to smallpox preparedness for the Canadian Armed Forces NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, [...]
PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections
28/10/2026
Company to host virtual Investor Day today at 11:30 AM ET, featuring key opinion leader Warren S. Joseph, DPM, FIDSA All scheduled FDA interactions on track and aligned with D-PLEX ₁₀₀ November 28, 2026 PDUFA goal date [...]
iTonic Holdings Ltd Regains Compliance with Nasdaq Minimum Bid Price Requirement
28/10/2026
BEIJING, China, Oct. 28, 2026 (GLOBE NEWSWIRE) -- iTonic Holdings Ltd (Nasdaq: ITOC) (the “Company”), a healthcare company focused on digital medical technologies, today announced that it has received a written notice [...]
Blue Lake Biotechnology Secures $5 Million Grant to Support Ongoing Pediatric Phase 1/2a Clinical Trial of Intranasal RSV Vaccine Candidate
28/10/2026
Funding will increase enrollment of children as young as 12 months old and explore the potential for BLB201 to reduce RSV transmission ATHENS, Ga. and SAN JOSE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Blue Lake [...]
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301
28/10/2026
- Both low dose and high dose BB-301 continue to drive robust improvements in swallowing function for dysphagic Patients with Oculopharyngeal Muscular Dystrophy (OPMD) - 100% of Patients treated with BB-301 across both [...]
Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
28/10/2026
• 135 patients, out of a total planned 182, have been randomized and were administered the first injection of Allocetra TM ; enrollment actively ongoing at clinical sites in the United States and in Europe • Topline six [...]
Immutep Receives A$2.16 million French R&D Tax Incentive
28/10/2026
SYDNEY, AUSTRALIA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today [...]
Filana Therapeutics Announces Publication in Cells of Promising Preclinical Findings for Simufilam in TSC2-Deficient Cells
28/10/2026
Findings provide new insight into simufilam’s effects on cellular stress responses and mitochondrial function New research demonstrates a 37% reduction in elevated ATF4, consistent with attenuation of the ATF4- [...]
Sofwave to Participate in Upcoming November Investor Conferences
28/10/2026
SAN CLEMENTE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today [...]
electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)
28/10/2026
Submission backed by clinical data from two clinical studies representing 168 subjects demonstrating quality of life improvements and an approximately 40% reduction in neuropathic pain scores in the active treatment [...]
Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial
28/10/2026
BRISBANE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that [...]
Noom Study Finds Members Further Along in Its GLP-1Rx Program Report Higher “Flourishing” and “Quality of Life”
28/10/2026
Analysis of 1,259 members of Noom’s GLP-1Rx Program finds clinically meaningful differences in anxiety, depression, fatigue, pain, cognition, social participation and overall health-related quality of life at Day 145 [...]
ORYZON to participate in upcoming events in November
28/10/2026
MADRID and CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its [...]
UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer
28/10/2026
Five-year Olympus follow-up data published in Therapeutic Advances in Urology reinforce the long-term durability of response with JELMYTO Results demonstrate sustained disease control through extended follow-up among [...]
INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement
28/10/2026
BOCA RATON, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a [...]
TCG Labs Soleil Highlights Portfolio Momentum with Three Programs Entering First-in-Human Clinical Trials Across Oncology and Cardiovascular Disease
28/10/2026
Fourth program advancing toward the clinic in respiratory disease with additional candidates progressing across areas of significant unmet need, further underscoring the productivity of TCG Labs Soleil’s in-house R& [...]
Neumarker Enter Collaboration to Advance Precision Medicine in Depression
28/10/2026
Collaboration aims to leverage AI-native brain intelligence to predict treatment response and enable more personalized depression care MOUNTAIN VIEW, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Neumarker, Inc., an AI- [...]
Scipher Medicine Launches PrismTcell™, the Next Molecular Treatment Response Signature, for Abatacept in Rheumatoid Arthritis
28/10/2026
Clinical validation study with PrismTcell use achieved approximately 2-fold higher ACR50 response rate to abatacept. DURHAM, N.C., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Scipher Medicine (Scipher), a leader in immunology [...]
Newron Pharmaceuticals to Participate in November Investor Conferences
28/10/2026
MILAN and MORRISTOWN, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with [...]

Pages